BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Ulcerative colitis clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for ulcerative colitis: 156 (84 sponsors; 33 newly posted in the last 180 days, 7 stopped in the last 180 days; 21 new-entrant sponsors). Momentum score 17.9, rank 34 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 23, Phase 2 49, Phase 3 36, Phase 4 7, N/A 40.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Janssen Research & Development, LLC | 11 | P3 8, P4 1, P2 1, NA 1 | 1 | 1 |
| AbbVie ABBV | 13 | P3 5, P2 2, NA 6 | 1 | 1 |
| Takeda TAK | 10 | P3 5, P2 2, NA 1, P4 2 | 0 | 1 |
| Hoffmann-La Roche | 5 | P3 4, P1 1 | 2 | 1 |
| Eli Lilly and Company LLY | 7 | P2 4, P3 3 | 0 | 1 |
| Pfizer PFE | 7 | P3 2, NA 3, P2 2 | 0 | 2 |
| Sanofi SNY | 6 | P1 1, P3 2, P2 3 | 1 | 1 |
| Merck Sharp & Dohme LLC MRK | 3 | P3 2, P2 1 | 0 | 0 |
| Bristol-Myers Squibb BMY | 5 | P3 1, NA 4 | 0 | 1 |
| Abivax S.A. ABVX | 2 | P3 1, P2 1 | 0 | 0 |
| Alfasigma S.p.A. | 2 | P3 1, NA 1 | 0 | 0 |
| Ganzhou Hemay Pharmaceutical Co., Ltd | 2 | P2 1, P3 1 | 1 | 1 |
| Vanda Pharmaceuticals VNDA new entrant | 1 | P3 1 | 1 | 0 |
| GlaxoSmithKline | 3 | P1 3 | 2 | 0 |
| Bausch Health Americas, Inc. | 2 | P4 2 | 0 | 1 |
| Biocad | 2 | P2 1, P1 1 | 0 | 1 |
| Eisai Korea Inc. | 2 | P4 1, NA 1 | 0 | 0 |
| Gilead Sciences GILD | 2 | P2 2 | 0 | 1 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | 2 | P1 1, P2 1 | 1 | 0 |
| Janssen Biotech, Inc. | 2 | NA 2 | 0 | 1 |
| Janssen-Cilag Ltd. | 2 | NA 2 | 1 | 0 |
| Palisade Bio PALI | 2 | P1 1, P2 1 | 1 | 0 |
| Spyre Therapeutics, Inc. SYRE | 2 | P2 2 | 1 | 0 |
| Accro Bioscience (Suzhou) Limited new entrant | 1 | P2 1 | 1 | 0 |
| Adacyte Therapeutics SL | 1 | NA 1 | 0 | 0 |
New-entrant sponsors: Vanda Pharmaceuticals, Accro Bioscience (Suzhou) Limited.
Recently stopped trials
- NCT07222189 Sanofi - terminated: Business decision A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Dise
- NCT06867094 Sanofi - terminated: Business decision A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
- NCT07250815 Takeda - withdrawn: Sponsor decision A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease
- NCT04277546 AstraZeneca - terminated: Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease. Open-label Extension Study of Brazikumab in Ulcerative Colitis
- NCT03616821 AstraZeneca - terminated: Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease. Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
- NCT06681389 NIBEC Co., Ltd. - terminated: Study was terminated at the end of Part A for strategic reasons (not due to lack of efficacy or safety issues A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative
- NCT05785715 AbbVie - terminated: Sponsor Decision\_Not Safety Related Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P2 | Shandong Suncadia Medicine Co., Ltd. | NCT07229950 A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease | Adult Patients With Moderately to Severely Active Ulcerative Colitis | recruiting | 48 |
| 2026-12-17 est. | P2 | Sanofi SNY | NCT06975722 A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis | Ulcerative Colitis | active not recruiting | 105 |
| 2026-12-30 est. | P2 | Ganzhou Hemay Pharmaceutical Co., Ltd | NCT05486104 Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis | Moderate to Severe Ulcerative Colitis | active not recruiting | 92 |
| 2027-01 est. | P2 | Gilead Sciences GILD | NCT06029972 Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | active not recruiting | 176 |
| 2027-01 est. | P2 | Biocad | NCT07080034 Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis | Ulcerative Colitis (UC) | recruiting | 198 |
| 2027-01-30 est. | P3 | Hoffmann-La Roche | NCT06589986 A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Sever | Moderately to Severely Active Ulcerative Colitis | active not recruiting | 400 |
| 2027-02-10 est. | P3 | Janssen Research & Development, LLC | NCT06260163 A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | Colitis, Ulcerative | active not recruiting | 112 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-29 est. | P3 | Hoffmann-La Roche | NCT06588855 A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulce | Moderately to Severely Active Ulcerative Colitis | active not recruiting | 350 |
| 2026-09-08 | P3 | Alfasigma S.p.A. | NCT02914535 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis | Ulcerative Colitis | completed | 1173 |
| 2026-08-12 | P3 | Merck Sharp & Dohme LLC MRK | NCT06052059 A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) | Ulcerative Colitis | active not recruiting | 1109 |
| 2026-08-03 | P2 | Eli Lilly and Company LLY | NCT06598943 A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis; Ulcerative Colitis Chronic | active not recruiting | 143 |
| 2026-07-30 est. | P2 | InventisBio Co., Ltd | NCT07035041 A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis | UC - Ulcerative Colitis; Moderately to Severely Active Ulcerative Colitis | active not recruiting | 120 |
| 2026-07-19 est. | P3 | AbbVie ABBV | NCT05316220 A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis | Ulcerative Colitis (UC) | withdrawn | |
| 2026-07-14 | P2 | Takeda TAK | NCT06254950 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis | active not recruiting | 213 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "ulcerative colitis"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.